S100B and amyotrophic lateral sclerosis: Receptor for advanced glycation end-products ligands showed increased immunostaining in ALS thoracic spinal cord vs. control samples (Figures 2B–D and 3B–D, Figure 4C) and analysis of immunofluorescence intensity was significantly higher in ALS tissue versus control for S100B, HMGB1 and CML, a prototype AGE protein (Figures 2E–G, respectively).